1. Home
  2. VYGR vs ARCT Comparison

VYGR vs ARCT Comparison

Compare VYGR & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

N/A

Current Price

$3.05

Market Cap

203.6M

Sector

Health Care

ML Signal

N/A

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

N/A

Current Price

$5.69

Market Cap

198.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VYGR
ARCT
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.6M
198.1M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
VYGR
ARCT
Price
$3.05
$5.69
Analyst Decision
Strong Buy
Buy
Analyst Count
2
10
Target Price
$16.50
$24.11
AVG Volume (30 Days)
750.5K
549.4K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.00
EPS
N/A
N/A
Revenue
$10,135,000.00
$82,031,000.00
Revenue This Year
$34.04
N/A
Revenue Next Year
$7.92
$12.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.88
$5.50
52 Week High
$5.55
$24.14

Technical Indicators

Market Signals
Indicator
VYGR
ARCT
Relative Strength Index (RSI) 36.64 33.61
Support Level $2.96 N/A
Resistance Level $4.33 $7.98
Average True Range (ATR) 0.18 0.35
MACD -0.02 -0.08
Stochastic Oscillator 10.71 12.62

Price Performance

Historical Comparison
VYGR
ARCT

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Share on Social Networks: